Laboratory of Microbial Immunochemistry and Vaccines, Ludwik Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, 53-114 Wroclaw, Poland.
Department of Pathogen Biology and Immunology, University of Wroclaw, 51-148 Wroclaw, Poland.
Int J Mol Sci. 2021 Oct 26;22(21):11562. doi: 10.3390/ijms222111562.
is considered one of the most critical multidrug-resistant pathogens and urgently requires new therapeutic strategies. Capsular polysaccharides (CPS), lipopolysaccharides (LPS), and exopolysaccharides (EPS) are the major virulence factors protecting against the immune response and thus may be targeted by phage-based therapeutics such as polysaccharides-degrading enzymes. Since the emergence of resistance to antibacterials is generally considered undesirable, in this study, the genetic and phenotypic characteristics of resistance to the phage-borne CPS-degrading depolymerase and its effect on virulence were investigated. The K63 serotype targeting depolymerase (KP36gp50) derived from siphovirus KP36 was used as the selective agent during the treatment of 486 biofilm. Genome-driven examination combined with the surface polysaccharide structural analysis of resistant mutant showed the point mutation and frameshift in the gene located within the gene cluster, resulting in the loss of the capsule. The sharp decline in the yield of CPS was accompanied by the production of a larger amount of smooth LPS. The modification of the surface polysaccharide layers did not affect bacterial fitness nor the insensitivity to serum complement; however, it made bacteria more prone to phagocytosis combined with the higher adherence and internalization to human lung epithelial cells. In that context, it was showed that the emerging resistance to the antivirulence agent (phage-borne capsule depolymerase) results in beneficial consequences, i.e., the sensitization to the innate immune response.
被认为是最关键的多药耐药性病原体之一,迫切需要新的治疗策略。荚膜多糖 (CPS)、脂多糖 (LPS) 和胞外多糖 (EPS) 是保护细菌免受免疫反应的主要毒力因子,因此可能成为噬菌体治疗的目标,如多糖降解酶。由于对抗菌药物的耐药性通常被认为是不可取的,因此在本研究中,研究了对噬菌体携带的 CPS 降解解聚酶的耐药性的遗传和表型特征及其对毒力的影响。来自 siphovirus KP36 的 K63 血清型靶向解聚酶 (KP36gp50) 被用作治疗 486 生物膜的选择性试剂。基于基因组的检查结合抗性突变体的表面多糖结构分析表明,位于 基因簇内的 基因发生点突变和移码,导致荚膜丢失。CPS 产量的急剧下降伴随着光滑 LPS 产量的增加。表面多糖层的修饰既不影响细菌的适应性,也不影响对血清补体的不敏感性;然而,它使细菌更容易被吞噬,同时与更高的粘附和内化到人类肺上皮细胞结合。在这种情况下,表明针对抗病毒剂(噬菌体携带的荚膜解聚酶)的新兴耐药性会产生有益的后果,即对先天免疫反应的敏感性增加。